Jesse Cedarbaum, MD, is a neurologist and clinical trialist with a sub-specialty in movement disorders at the Yale School of Medicine. His career focus has been on the development of novel and improved therapeutic agents for neurodegenerative and neuropsychiatric disorders. He has led teams developing both small molecule, protein and antisense therapeutics in all stages of the development process, including preclinical development, Phase 1, translational and “Proof of Concept” studies, Phase 3 clinical studies and associated regulatory activities. He has also played key roles in the development of several currently marketed products, both as an academic investigator and industry team leader and executive.
Jesse Cedarbaum, MD
Yale University | New Haven, USA
Jesse Cedarbaum, MD, is a neurologist and clinical trialist with a sub-specialty in movement disorders at the Yale School of Medicine. His career focus has been on the development of novel and improved therapeutic agents for neurodegenerative and neuropsychiatric disorders. He has led teams developing both small molecule, protein and antisense therapeutics in all stages of the development process, including preclinical development, Phase 1, translational and “Proof of Concept” studies, Phase 3 clinical studies and associated regulatory activities. He has also played key roles in the development of several currently marketed products, both as an academic investigator and industry team leader and executive.
